Review





Similar Products

nlrp3 inhibitor mcc950  (MedChemExpress)
99
MedChemExpress nlrp3 inhibitor mcc950
8-oxo-Guo and polyU stimulate inflammation via NLR and TLR signaling pathways. (A, B) Transcriptome analysis of MH-S cells following 2-h stimulation with 8-oxo-Guo and/or polyU. (A) KEGG pathway enrichment analysis. (B) GSEA. (C) Relative mRNA expression levels of NOD2 , TLR2 , and <t>NLRP3</t> in cells after 2-h stimulation with 8-oxo-Guo and/or polyU. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (D) Protein expression changes and grayscale quantification of key components of NLR, TLR, MAPK, JAK-STAT, and NF-κB signaling pathways following 2-h stimulation with 8-oxo-Guo and/or polyU. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Nlrp3 Inhibitor Mcc950, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nlrp3+inhibitor+(mcc950/MCC950/pmc13223851-69-6-13
Average 99 stars, based on 1 article reviews
nlrp3 inhibitor mcc950 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
nlrp3 inhibitor mcc950  (InvivoGen)
96
InvivoGen nlrp3 inhibitor mcc950
The impact of SYK inhibition on <t>NLRP3</t> activation. Cells were treated with VLPs (20 µg/mL) and mAbs (7.5 µg/mL) for 24 h, and 1 µM of SYK inhibitor R406 or NLRP3 inhibitor <t>MCC950</t> was added 1 h before treatment. (A) Western blot data show the expression of the indicated protein in microglia lysates, and the images are representative of five to six experiments. (B) Quantification of NLRP3 expression from Western blot data, normalised to a loading control, N = 5–6. (C) Quantification of ASC speck formation in primary microglia, N = 6. (D, E) IL‐1β secretion and (F) TNF‐α secretion were tested by ELISA in microglia supernatants, (D) N = 4, (E) N = 4–6, (F) N = 8–9. (G) Fluorescent microscopy images of the immunostained NLRP3 (cyan) and ASC specks (yellow), NLRP3 was stained with primary Ab anti‐NLRP and secondary Ab—AlexaFluor 488, ASC specks were stained with primary Ab anti‐ASC‐PE. Representative images are shown. The scale bars indicate 50 µm in large images and 20 µm in magnified images. In (B–F), data are represented using a box plot with dots showing the number of individual experiments. Significance was established using one‐way ANOVA followed by Tukey's test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Nlrp3 Inhibitor Mcc950, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nlrp3+inhibitor+(mcc950/MCC950/pmc13139746-43-5-14
Average 96 stars, based on 1 article reviews
nlrp3 inhibitor mcc950 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
nlrp3 specific inhibitor mcc950  (MedChemExpress)
99
MedChemExpress nlrp3 specific inhibitor mcc950
The impact of SYK inhibition on <t>NLRP3</t> activation. Cells were treated with VLPs (20 µg/mL) and mAbs (7.5 µg/mL) for 24 h, and 1 µM of SYK inhibitor R406 or NLRP3 inhibitor <t>MCC950</t> was added 1 h before treatment. (A) Western blot data show the expression of the indicated protein in microglia lysates, and the images are representative of five to six experiments. (B) Quantification of NLRP3 expression from Western blot data, normalised to a loading control, N = 5–6. (C) Quantification of ASC speck formation in primary microglia, N = 6. (D, E) IL‐1β secretion and (F) TNF‐α secretion were tested by ELISA in microglia supernatants, (D) N = 4, (E) N = 4–6, (F) N = 8–9. (G) Fluorescent microscopy images of the immunostained NLRP3 (cyan) and ASC specks (yellow), NLRP3 was stained with primary Ab anti‐NLRP and secondary Ab—AlexaFluor 488, ASC specks were stained with primary Ab anti‐ASC‐PE. Representative images are shown. The scale bars indicate 50 µm in large images and 20 µm in magnified images. In (B–F), data are represented using a box plot with dots showing the number of individual experiments. Significance was established using one‐way ANOVA followed by Tukey's test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Nlrp3 Specific Inhibitor Mcc950, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nlrp3+inhibitor+(mcc950/MCC950/pm42431105-111-37-42
Average 99 stars, based on 1 article reviews
nlrp3 specific inhibitor mcc950 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
nlrp3 inflammasome inhibitor mcc950  (MedChemExpress)
99
MedChemExpress nlrp3 inflammasome inhibitor mcc950
The impact of SYK inhibition on <t>NLRP3</t> activation. Cells were treated with VLPs (20 µg/mL) and mAbs (7.5 µg/mL) for 24 h, and 1 µM of SYK inhibitor R406 or NLRP3 inhibitor <t>MCC950</t> was added 1 h before treatment. (A) Western blot data show the expression of the indicated protein in microglia lysates, and the images are representative of five to six experiments. (B) Quantification of NLRP3 expression from Western blot data, normalised to a loading control, N = 5–6. (C) Quantification of ASC speck formation in primary microglia, N = 6. (D, E) IL‐1β secretion and (F) TNF‐α secretion were tested by ELISA in microglia supernatants, (D) N = 4, (E) N = 4–6, (F) N = 8–9. (G) Fluorescent microscopy images of the immunostained NLRP3 (cyan) and ASC specks (yellow), NLRP3 was stained with primary Ab anti‐NLRP and secondary Ab—AlexaFluor 488, ASC specks were stained with primary Ab anti‐ASC‐PE. Representative images are shown. The scale bars indicate 50 µm in large images and 20 µm in magnified images. In (B–F), data are represented using a box plot with dots showing the number of individual experiments. Significance was established using one‐way ANOVA followed by Tukey's test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Nlrp3 Inflammasome Inhibitor Mcc950, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nlrp3+inhibitor+(mcc950/MCC950/pm42378757-79-12-18
Average 99 stars, based on 1 article reviews
nlrp3 inflammasome inhibitor mcc950 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

Image Search Results


8-oxo-Guo and polyU stimulate inflammation via NLR and TLR signaling pathways. (A, B) Transcriptome analysis of MH-S cells following 2-h stimulation with 8-oxo-Guo and/or polyU. (A) KEGG pathway enrichment analysis. (B) GSEA. (C) Relative mRNA expression levels of NOD2 , TLR2 , and NLRP3 in cells after 2-h stimulation with 8-oxo-Guo and/or polyU. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (D) Protein expression changes and grayscale quantification of key components of NLR, TLR, MAPK, JAK-STAT, and NF-κB signaling pathways following 2-h stimulation with 8-oxo-Guo and/or polyU. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Journal: Redox Biology

Article Title: 8-oxo-7,8-dihydroguanosine (8-oxo-Guo) drives pulmonary inflammatory pathways through pattern recognition receptors

doi: 10.1016/j.redox.2026.104211

Figure Lengend Snippet: 8-oxo-Guo and polyU stimulate inflammation via NLR and TLR signaling pathways. (A, B) Transcriptome analysis of MH-S cells following 2-h stimulation with 8-oxo-Guo and/or polyU. (A) KEGG pathway enrichment analysis. (B) GSEA. (C) Relative mRNA expression levels of NOD2 , TLR2 , and NLRP3 in cells after 2-h stimulation with 8-oxo-Guo and/or polyU. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (D) Protein expression changes and grayscale quantification of key components of NLR, TLR, MAPK, JAK-STAT, and NF-κB signaling pathways following 2-h stimulation with 8-oxo-Guo and/or polyU. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: The NOD2 inhibitor GSK717 (HY-136555) and NLRP3 inhibitor MCC950 (HY-12815A) were obtained from MedChemExpress (MCE), and the TLR2 inhibitor Cu-CPT22 (S8677) was obtained from Selleck.

Techniques: Protein-Protein interactions, Expressing

Dose-dependent suppression of 8-oxo-Guo/polyU-induced inflammation upon NOD2, TLR2, and NLRP3 inhibition. (A-F) Protein expression changes in NLR, TLR, and downstream signaling pathways (left panels) and concentrations of TNF-α, MIP-2, IL-1β, and MCP-1 in the culture supernatant (right panels) of MH-S cells following 4-h co-stimulation with 8-oxo-Guo and polyU in the presence of GSK717 (A, B) , Cu-CPT22 (C, D) , or MCC950 (E, F) . ∗∗ p < 0.01, ∗∗∗ p < 0.001. (G, H) Protein expression profiles of relevant signaling pathways (G) and cytokine concentrations in the culture supernatant (H) of MH-S cells that were treated for 4 h with 8-oxo-Guo and polyU combined with GSK717, Cu-CPT22, or MCC950, either individually or combined. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Journal: Redox Biology

Article Title: 8-oxo-7,8-dihydroguanosine (8-oxo-Guo) drives pulmonary inflammatory pathways through pattern recognition receptors

doi: 10.1016/j.redox.2026.104211

Figure Lengend Snippet: Dose-dependent suppression of 8-oxo-Guo/polyU-induced inflammation upon NOD2, TLR2, and NLRP3 inhibition. (A-F) Protein expression changes in NLR, TLR, and downstream signaling pathways (left panels) and concentrations of TNF-α, MIP-2, IL-1β, and MCP-1 in the culture supernatant (right panels) of MH-S cells following 4-h co-stimulation with 8-oxo-Guo and polyU in the presence of GSK717 (A, B) , Cu-CPT22 (C, D) , or MCC950 (E, F) . ∗∗ p < 0.01, ∗∗∗ p < 0.001. (G, H) Protein expression profiles of relevant signaling pathways (G) and cytokine concentrations in the culture supernatant (H) of MH-S cells that were treated for 4 h with 8-oxo-Guo and polyU combined with GSK717, Cu-CPT22, or MCC950, either individually or combined. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: The NOD2 inhibitor GSK717 (HY-136555) and NLRP3 inhibitor MCC950 (HY-12815A) were obtained from MedChemExpress (MCE), and the TLR2 inhibitor Cu-CPT22 (S8677) was obtained from Selleck.

Techniques: Inhibition, Expressing, Protein-Protein interactions

The impact of SYK inhibition on NLRP3 activation. Cells were treated with VLPs (20 µg/mL) and mAbs (7.5 µg/mL) for 24 h, and 1 µM of SYK inhibitor R406 or NLRP3 inhibitor MCC950 was added 1 h before treatment. (A) Western blot data show the expression of the indicated protein in microglia lysates, and the images are representative of five to six experiments. (B) Quantification of NLRP3 expression from Western blot data, normalised to a loading control, N = 5–6. (C) Quantification of ASC speck formation in primary microglia, N = 6. (D, E) IL‐1β secretion and (F) TNF‐α secretion were tested by ELISA in microglia supernatants, (D) N = 4, (E) N = 4–6, (F) N = 8–9. (G) Fluorescent microscopy images of the immunostained NLRP3 (cyan) and ASC specks (yellow), NLRP3 was stained with primary Ab anti‐NLRP and secondary Ab—AlexaFluor 488, ASC specks were stained with primary Ab anti‐ASC‐PE. Representative images are shown. The scale bars indicate 50 µm in large images and 20 µm in magnified images. In (B–F), data are represented using a box plot with dots showing the number of individual experiments. Significance was established using one‐way ANOVA followed by Tukey's test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: European Journal of Immunology

Article Title: SYK Signalling in NLRP3 Inflammasome‐Mediated Response of Murine Microglia Activated by Immune Complexes Formed of Viral Proteins and Specific IgG

doi: 10.1002/eji.70199

Figure Lengend Snippet: The impact of SYK inhibition on NLRP3 activation. Cells were treated with VLPs (20 µg/mL) and mAbs (7.5 µg/mL) for 24 h, and 1 µM of SYK inhibitor R406 or NLRP3 inhibitor MCC950 was added 1 h before treatment. (A) Western blot data show the expression of the indicated protein in microglia lysates, and the images are representative of five to six experiments. (B) Quantification of NLRP3 expression from Western blot data, normalised to a loading control, N = 5–6. (C) Quantification of ASC speck formation in primary microglia, N = 6. (D, E) IL‐1β secretion and (F) TNF‐α secretion were tested by ELISA in microglia supernatants, (D) N = 4, (E) N = 4–6, (F) N = 8–9. (G) Fluorescent microscopy images of the immunostained NLRP3 (cyan) and ASC specks (yellow), NLRP3 was stained with primary Ab anti‐NLRP and secondary Ab—AlexaFluor 488, ASC specks were stained with primary Ab anti‐ASC‐PE. Representative images are shown. The scale bars indicate 50 µm in large images and 20 µm in magnified images. In (B–F), data are represented using a box plot with dots showing the number of individual experiments. Significance was established using one‐way ANOVA followed by Tukey's test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: SYK kinase inhibitor R406 (#inh‐r406), NLRP3 inhibitor MCC950 (#inh‐mcc), and Zymosan (#tlrl‐zyn) were from Invivogen.

Techniques: Inhibition, Activation Assay, Western Blot, Expressing, Control, Enzyme-linked Immunosorbent Assay, Microscopy, Staining